Innate Pharma S.A.

IPHA

$2.11

-2.76%

N/A-$0.06

Healthcare

Biotechnology

NASDAQ

Active Trading

Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and ...

Financial Highlights of IPHA

Profitability trend

Latest / TTM · 6 periods

Gross Margin

100.0%

Net Margin

-1764.5%

P/E Ratio

-3.23x

n/a

Debt / Equity

-1.04

n/a

Current Ratio

1.27

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

100.0%

Net Margin

-1764.5%

P/E Ratio

-3.23x

Debt / Equity

-1.04

Profitability

Profitability table

Metric	2021	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	-184.1%	10.4%	10.8%	100.0%	100.0%	—
Operating MarginOperating income as a percentage of revenue.	-394.9%	-99.6%	-24.4%	-408.6%	-1916.9%	—
Net MarginNet income as a percentage of revenue.	-436.0%	-100.7%	-14.6%	-392.0%	-1764.5%	—
EBITDA MarginEBITDA divided by revenue.	-356.9%	-21.3%	-3.5%	-371.7%	-1566.1%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	-375.5%	-100.5%	-14.6%	-392.0%	-1764.5%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2021	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	1.73	3.38	3.73	2.60	1.27	—
Quick RatioLiquid assets divided by current liabilities.	1.73	3.38	3.73	2.60	1.27	—
Cash RatioCash and equivalents divided by current liabilities.	1.30	2.04	1.78	2.01	0.77	—
Debt / AssetsDebt as a share of total assets.	16.5%	20.3%	22.8%	27.9%	36.0%	—
Debt / EquityDebt compared with shareholder equity.	0.41	0.78	0.77	3.51	-1.04	—

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	7.30x	18.36x	1.12x	7.68x	0.37x	—
Inventory TurnoverHow often inventory is sold in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Payables TurnoverHow often payables are paid in a year.	3.19x	3.78x	6.54x	6.56x	0.00x	—
Asset TurnoverRevenue generated per dollar of assets.	0.05x	0.28x	0.30x	0.11x	0.04x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	0.13x	0.74x	0.50x	0.16x	0.09x	—

Valuation ratios

Valuation ratios table

Metric	2021	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	-7.04x	-4.77x	-28.15x	-2.91x	-2.81x	—
P/B RatioPrice paid for each dollar of book value.	2.97x	5.12x	4.11x	16.30x	-6.14x	—
P/S RatioPrice paid for each dollar of sales.	26.34x	4.81x	4.11x	11.41x	47.79x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-5.34x	-13.67x	-6.10x	-19.76x	-3.81x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	0.0%	0.0%	—

Upstream

Rentschler Fill Solutions GmbH (RFS)Unspecified CDMOs (antibody drug substance manufacturers)Clinical CROs (likely IQVIA or equivalent)Specialty reagent & raw material suppliers (antibody expression systems, cell culture media)

Downstream

SanofiEURONEXT:SANAstraZenecaNASDAQ:AZN Takeda Pharmaceutical CompanyNYSE:TAK Novo NordiskNYSE:NVO Bristol-Myers SquibbNYSE:BMY

Proxies

argenx SENASDAQ:ARGX Genmab A/SNASDAQ:GMABMorphoSys AG (now part of Novartis)UnconfirmedImmunoGen (now part of AbbVie)Unconfirmed

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

Innate Pharma S.A.

Financial Highlights of IPHA

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of IPHA

Upstream

Downstream

Proxies

Financial Highlights of IPHA

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of IPHA

Upstream

Downstream

Proxies